Supercritical CO2 extraction is also the key to understanding more cannabinoids in cannabis like Cannabichromene (CBC) and cannabicitran (CBT) and how they interact with each other (called the Entourage effect). This can lead to increased understanding of marijuana in the medical field, and will also allow growers to come up with more effective, new and exciting strains.
CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.
CBD—or cannabidiol—is a type of cannabinoid, a family of molecules typically associated with marijuana, but in fact, also found in other plants and even humans (in us, they’re called endocannabinoids). There are hundreds of different cannabinoids in marijuana. The best known is tetrahydrocannabinol, or THC, a chemical in marijuana that targets and binds to certain receptors in the brain to give you a high. CBD is non-psychoactive and non-addictive, and it seems to bind to multiple target sites, thereby affecting a range of systems throughout the body.
CBD has become quite popular over the last couple of years but despite what you might think, it is only one of the 100+ compounds that have been identified in the Cannabis Sativa L plant. Full Spectrum CBD oil, unlike CBD isolate products, includes a wide range of cannabinoids present in the cannabis or hemp plant. Depending on the condition and what you are looking to achieve, it can provide a greater effect than CBD alone as all the cannabinoids work together in what is known as the entourage effect (more on that later).
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×